Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + Apatinib vs Fluzoparib in Relapsed Ovarian Cancer
NCT05479487Phase 2Not yet recruiting
- Start
- Aug 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in ovarian cancer. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05479487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05479487.